Key points are not available for this paper at this time.
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
David Cunningham
Yves Humblet
Salvatore Siena
New England Journal of Medicine
Sorbonne Université
UCLouvain
Pitié-Salpêtrière Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Cunningham et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699ffdb052ece5d8a806922b — DOI: https://doi.org/10.1056/nejmoa033025